Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

136.08 -0.24 (-0.18%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ascendis Pharma ADR

3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ: ASND Investor Alert: Investigation over Potential Wrongdoing at Ascendis Pharma A/S
San Diego, CA -- (SBWIRE) -- 06/20/2023 -- Certain directors of Ascendis Pharma A/S are under investigation over potential breaches of fiduciary duties by certain directors. 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NASDAQ: ASND Shareholder Notice: Investigation over Possible Securities Laws Violations by Ascendis Pharma A/S
San Diego, CA -- (SBWIRE) -- 04/17/2023 -- Ascendis Pharma A/S is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation - ASND
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
ASCENDIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ascendis Pharma A/S on Behalf of Ascendis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ascendis Pharma A/S (ASND) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ascendis Pharma A/S and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
ASND LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
From The Rosen Law Firm, P.A.
Via Business Wire
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.